SIRT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Dual treatment with SIRT1 and tyrosine kinase inhibitors (TKI) reduces CML cell proliferation, mitochondrial gene suppression and subsequent cell death in transgenic CML mouse model (51).